USPTO’s Arthrex guidance offers window into agency’s thinking
Amid mounting speculation over the uncertainty caused by the US Supreme Court decision’s landmark decision in US v Arthrex, the United States Patent and Trademark Office (USPTO) has posted several updates issuing guidance. But lawyers tell WIPR that some key questions remain.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
3 November 2020 In October, the US Supreme Court agreed to hear Arthrex v Smith & Nephew. Jason Romrell, Derek McCorquindale, and Brandon Andersen of Finnegan, Henderson, Farabow, Garrett & Dunner, outline what this means.
23 July 2021 Despite the latest challenge to its legitimacy, the US Patent Trial and Appeal Board has survived—and survive it must, say David McCombs, Joe Matal, and Eugene Goryunov of Haynes and Boone.